NAFDAC and National Counter Terrorism Centre Collaborate Against Counterfeit Drugs

Saturday, 7 September 2024, 23:21

NAFDAC has signed a MoU with the National Counter Terrorism Centre to combat counterfeit drugs effectively. This collaboration aims to enhance drug safety and ensure public health. The partnership emphasizes the importance of protecting consumers from the dangers posed by fraudulent pharmaceuticals.
LivaRava_Medicine_Default.png
NAFDAC and National Counter Terrorism Centre Collaborate Against Counterfeit Drugs

NAFDAC Collaborates with National Counter Terrorism Centre

The National Agency for Food and Drug Administration and Control (NAFDAC) has taken significant steps to improve drug safety by entering into a Memorandum of Understanding (MoU) with the National Counter Terrorism Centre. This alliance aims to combat counterfeit drugs, a growing concern in the pharmaceutical sector.

Significance of the Collaboration

This collaboration is crucial for enhancing consumer protection and safeguarding public health. Counterfeit medications pose serious risks, and through this partnership, both organizations are committed to ensuring the integrity of the drug supply chain.

Key Objectives of the MoU

  • Strengthening regulatory frameworks
  • Enhancing intelligence sharing
  • Promoting public awareness on the dangers of counterfeit drugs

This initiative marks a significant milestone in the ongoing battle against drug-related crimes.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe